The display will show 0.25 mg or 0.5 mg for the redlabel pen, 1 mg for the blue-label pen, and 2 mg for the yellow-label pen
The economic impact in these settings is profound, with average treatment costs around $10,000 per patient-often exceeding the monthly income of a typical household
The Zepbound (tirzepatide) label recommends switching to a non-oral birth control method, or adding a barrier method, for 4 weeks after starting Zepbound and for 4 weeks after each dose increase
For others, it may develop over time, leading to chronic gastritis
Our medical team provides ongoing guidance, education, and support to help ensure safe use and long-term success